Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of the Pharmacokinetics, Safety, and Tolerability of ALKS 5461 in Subjects With Hepatic Impairment

NCT02452801 is registered in ClinicalTrials.gov with Alkermes, Inc. as lead sponsor.

NCT NCT02452801
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02452801 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of the Pharmacokinetics, Safety, and Tolerability of ALKS 5461 in Subjects With Hepatic Impairment
Lead sponsor
Alkermes, Inc.
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2015
Completion date
December 31, 2015
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatic impairment